Next‐generation balloon‐expandable Myval transcatheter heart valve in low‐risk aortic stenosis patients

2021 ◽  
Author(s):  
Mario García‐Gómez ◽  
Jose Raúl Delgado‐Arana ◽  
Jonathan Halim ◽  
Federico De Marco ◽  
Carlo Trani ◽  
...  
Keyword(s):  
Aortic Stenosis ◽  
Heart Valve ◽  
Low Risk ◽  
Next Generation ◽  
Transcatheter Heart Valve

scholarly journals A Novel Self-Expandable Transcatheter Heart Valve for Aortic Stenosis Implanted via a Direct Percutaneous Transaxillary Approach

2017 ◽  
Vol 65 (S 01) ◽  
pp. S1-S110
Author(s):  
F. Deuschl ◽  
N. Schofer ◽  
M. Seiffert ◽  
S. Hakmi ◽  
I. Mizote ◽  
...  
Keyword(s):  
Aortic Stenosis ◽  
Heart Valve ◽  
Transaxillary Approach ◽  
Transcatheter Heart Valve

Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis

2021 ◽  
Vol 17 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Samin K Sharma ◽  
Ravinder S Rao ◽  
Manik Chopra ◽  
Anmol Sonawane ◽  
John Jose ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Heart Valve ◽  
Future Research ◽  
Surgical Aortic Valve Replacement ◽  
Surgical Risk ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve

The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems. Myval™ THV (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India) is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes. This review summarizes existing preclinical and clinical data on Myval THV for the intervention of symptomatic native AS and lays out the plan for future research program.

How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?

2010 ◽  
Vol 11 (10) ◽  
pp. 727-732 ◽  
Author(s):  
Francesco Saia ◽  
Cinzia Marrozzini ◽  
Gianni DallʼAra ◽  
Vincenzo Russo ◽  
Sofia Martìn-Suàrez ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Aortic Stenosis ◽  
Heart Valve ◽  
Transcatheter Heart Valve ◽  
Valve Implantation
Sign in / Sign up

Export Citation Format

Share Document